ESR1 and breast carcinoma: A recent study has shown that miR-19a-3p, which decreases CYP19A1 expression, was overexpressed in breast cancer plasma patients and reduced the sensitivity of ER+ breast cancer cells to one of the AIs, letrozole [161].